<DOC>
	<DOCNO>NCT02492984</DOCNO>
	<brief_summary>An open-label , single-arm , post- authorization pragmatic clinical trial safety efficacy Xyntha ( Moroctocog-alfa ( AF-CC ) , Recombinant FVIII ) subject hemophilia A usual care setting China approximately 6 month approximately 50 exposure day whichever occur first</brief_summary>
	<brief_title>PF-05208756 , Moroctocog Alfa ( AF-CC ) , Xyntha For Hemophilia A</brief_title>
	<detailed_description>The purpose post-approval study provide supplementary information relate use Xyntha ( Moroctocog-alfa ( AF-CC ) , Recombinant FVIII ) Chinese subject hemophilia A , especially safety efficacy different population Chinese hemophilia A patient , particular pediatric patient &lt; 6 year age , pediatric patient ≥6 ≤12 year age , Previously Untreated Patients ( PUPs ) , subject receive prophylaxis treatment enrollment study , severe patient ( FVIII : C &lt; 1 % ) .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male and/or Female subject Hemophilia A. Subjects/parents/legal representative must able comply registry procedure ( informed consent/assent process , clinical visit , report infusion bleed data , report adverse event , etc ) . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative , parent ( ) /legal guardian ) inform pertinent aspect study . Presence bleed disorder addition hemophilia A . Treatment immunomodulatory therapy ( e.g. , intravenous immunoglobulin , routine systemic corticosteroid , cyclosporins , antiTNF agent ) within 30 day prior study entry plan use duration study participation . Subjects past history , current factor VIII inhibitor . For laboratorybased assessment , Bethesda inhibitor titer great laboratory 's normal range ≥0.6 BU/mL . Subjects know hypersensitivity active substance excipients Xyntha . Subjects know hypersensitivity Chinese Hamster Ovary cell protein . Unwilling unable follow term protocol . Any condition may compromise subject 's ability comply and/or perform studyrelated activity pose clinical contraindication study participation ( condition include , limited , inadequate medical history assure study eligibility ; expectation poor compliance provision observation studyrelated documentation ) , opinion Investigator . Participation study involve investigational drug ( ) ( Phases 14 ) within 30 day current study begin and/or study participation ( exception study Xyntha ) . Subjects investigational site staff member directly involved conduct study family member , site staff member otherwise supervised Investigator , subject Pfizer employee directly involve conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FVIII inhibitor</keyword>
</DOC>